Content Conference Coverage Conferences IDWeek 2016
IDWeek 2016: Tenofovir Alafenamide Works Well and Improves Kidney and Bone Markers in Older HIV Patients
- Details
- Category: Approved HIV Drugs
- Created on Sunday, 06 November 2016 00:00
A coformulation of tenofovir alafenamide (TAF) plus emtricitabine, used with a third antiretroviral drug, maintained viral suppression as well as tenofovir disoproxil fumarate (TDF) plus emtricitabine in older individuals, and was associated with improvements in kidney function and bone density, which may be of greater concern for this group, according to a presentation last week at IDWeek 2106 in New Orleans.
IDWeek 2016: Omega-3 Fatty Acids May Improve Triglycerides and Inflammation in HIV+ People
- Details
- Category: Approved HIV Drugs
- Created on Sunday, 06 November 2016 00:00
Long-term use of omega-3 fatty acid supplements was associated with reduced levels of triglycerides and the inflammation biomarker C-reactive protein (CRP) in HIV-positive people with suppressed viral load, according to research presented last week at IDWeek 2016 in New Orleans.
IDWeek 2016: Ibalizumab Monoclonal Antibody Looks Promising for HIV Patients Left Behind
- Details
- Category: Experimental HIV Drugs
- Created on Saturday, 29 October 2016 00:00
Ibalizumab, an experimental antiretroviral agent that works differently than existing HIV drugs, demonstrated promising safety and antiviral activity in a small Phase 3 study of people with highly drug-resistant virus, according to a report at the IDWeek conference this week in New Orleans. If confirmed in larger studies, this could be good news for HIV patients who cannot be successfully treated using available therapies.
IDWeek 2016: Dolutegravir Regimen Works Better than Atazanavir in Clinical Trial for Women
- Details
- Category: Approved HIV Drugs
- Created on Monday, 31 October 2016 00:00
A once-daily regimen containing the potent HIV integrase inhibitor dolutegravir worked better than an older atazanavir-containing regimen -- with higher rates of viral suppression both overall and across race subgroups -- in the ARIA trial, one of the few antiretroviral therapy studies to enroll only women, according to a presentation at IDWeek last week in New Orleans.
New Research Sheds Light on Origin of HIV in U.S., Dispelling Patient Zero Myth
- Details
- Category: HIV Prevention
- Created on Wednesday, 02 November 2016 00:00
A new genetic analysis shows that HIV likely spread from the Caribbean to New York City around 1971 and from there to San Francisco around 1976, laying to rest the misconception that a Canadian flight attendant, Gaetan Dugas, was responsible for sparking the epidemic in the United States.
More Articles...
- IDWeek 2016: Do HIV-Positive Men with Undetectable Viral Load Need to Wear Condoms?
- IDWeek 2016: Comorbidities Are Common and Rising Among People with HIV
- IDWeek 2016: New Triple DAA Combo Cures 96%-99% of People with Genotype 1-6 Hepatitis C
- Young Adolescents Need Only 2 Doses of Human Papillomavirus Vaccine, CDC Says
Web Design and Development by